title: Mmp-9 inhibition: a therapeutic strategy in ischemic stroke.
abstract: Ischemic stroke is a leading cause of disability worldwide. In cerebral ischemia there is an enhanced expression of matrix metallo-proteinase-9 (MMP-9), which has been associated with various complications including excitotoxicity, neuronal damage, apoptosis, blood-brain barrier (BBB) opening leading to cerebral edema, and hemorrhagic transformation. Moreover, the tissue plasminogen activator (tPA), which is the only US-FDA approved treatment of ischemic stroke, has a brief 3 to 4 h time window and it has been proposed that detrimental effects of tPA beyond the 3 h since the onset of stroke are derived from its ability to activate MMP-9 that in turn contributes to the breakdown of BBB. Therefore, the available literature suggests that MMP-9 inhibition can be of therapeutic importance in ischemic stroke. Hence, combination therapies of MMP-9 inhibitor along with tPA can be beneficial in ischemic stroke. In this review we will discuss the current status of various strategies which have shown neuroprotection and extension of thrombolytic window by directly or indirectly inhibiting MMP-9 activity. In the introductory part of the review, we briefly provide an overview on ischemic stroke, commonly used models of ischemic stroke and a role of MMP-9 in ischemia. In next part, the literature is organized as various approaches which have proven neuroprotective effects through direct or indirect decrease in MMP-9 activity, namely, using biotherapeutics, involving MMP-9 gene inhibition using viral vectors; using endogenous inhibitor of MMP-9, repurposing of old drugs such as minocycline, new chemical entities like DP-b99, and finally other approaches like therapeutic hypothermia.
authors.affiliation: Laboratory of Neurobiology, Nencki Institute, Pasteura 3, 02-093, Warsaw, Poland, m.chaturvedi@nencki.gov.pl.
authors.forename: Mayank
authors.initials: M
authors.lastname: Chaturvedi
authors.forename: Leszek
authors.initials: L
authors.lastname: Kaczmarek
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000639:trends; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D020521:Stroke / Q000188:drug therapy* / Q000201:enzymology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D018696:Neuroprotective Agents; D010959:Tissue Plasminogen Activator; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
references.citation: Circulation. 2003 Feb 4;107(4):598-603
references.pmid: 12566373
references.citation: Stroke. 2008 Jun;39(6):1774-8
references.pmid: 18403736
references.citation: Neurosci Lett. 1997 Nov 28;238(1-2):53-6
references.pmid: 9464653
references.citation: Dev Neurosci. 2012;34(5):417-27
references.pmid: 23171520
references.citation: Neurobiol Dis. 2011 Oct;44(1):28-37
references.pmid: 21689752
references.citation: J Neurotrauma. 2009 Nov;26(11):1935-41
references.pmid: 19469687
references.citation: J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7
references.pmid: 15674236
references.citation: Mol Cell Neurosci. 2003 Jan;22(1):98-106
references.pmid: 12595242
references.citation: J Neurosci. 2007 Feb 14;27(7):1511-8
references.pmid: 17301159
references.citation: Immunol Invest. 2012;41(4):337-55
references.pmid: 21864113
references.citation: Brain Inj. 2013;27(10):1190-8
references.pmid: 23895636
references.citation: J Transl Med. 2009 Nov 17;7:97
references.pmid: 19919699
references.citation: J Am Acad Dermatol. 2006 Feb;54(2):258-65
references.pmid: 16443056
references.citation: Stroke. 2004 Sep;35(9):2220-5
references.pmid: 15284446
references.citation: Cardiovasc Psychiatry Neurol. 2009;2009:904836
references.pmid: 20037727
references.citation: Exp Transl Stroke Med. 2009 Nov 13;1:7
references.pmid: 20150985
references.citation: Stroke. 1996 Sep;27(9):1578-85
references.pmid: 8784133
references.citation: Annu Rev Cell Dev Biol. 2001;17:463-516
references.pmid: 11687497
references.citation: Transl Stroke Res. 2011 Jun 1;2(2):202-8
references.pmid: 21909339
references.citation: J Neurosci. 2010 Nov 17;30(46):15337-57
references.pmid: 21084591
references.citation: Neurosurg Focus. 2011 Jun;30(6):E17
references.pmid: 21631218
references.citation: Acta Neurochir Suppl. 2011;111:295-8
references.pmid: 21725771
references.citation: Stroke. 1998 May;29(5):1020-30
references.pmid: 9596253
references.citation: Nat Rev Neurosci. 2012 Nov;13(11):743-57
references.pmid: 23047773
references.citation: Clin Neuropharmacol. 2004 Nov-Dec;27(6):293-8
references.pmid: 15613934
references.citation: Eur J Neurosci. 2002 Jan;15(1):19-32
references.pmid: 11860503
references.citation: Biochem Biophys Res Commun. 1992 Oct 30;188(2):740-5
references.pmid: 1445318
references.citation: Exp Neurol. 2009 Mar;216(1):35-46
references.pmid: 19073180
references.citation: BMC Neurosci. 2009 Jun 04;10:56
references.pmid: 19497125
references.citation: Neuroscience. 2012 Sep 27;221:47-55
references.pmid: 22766232
references.citation: J Neurochem. 2010 Jan;112(1):134-49
references.pmid: 19840223
references.citation: Stroke. 2011 Oct;42(10):e566; author reply e567
references.pmid: 21903959
references.citation: J Neurosci. 2005 Jul 6;25(27):6401-8
references.pmid: 16000631
references.citation: Brain Res. 2008 Jan 10;1188:198-206
references.pmid: 18031717
references.citation: Stroke. 2003 Jun;34(6):e48-50
references.pmid: 12750540
references.citation: J Stroke Cerebrovasc Dis. 2011 Jan-Feb;20(1):47-54
references.pmid: 21044610
references.citation: Curr Neuropharmacol. 2009 Dec;7(4):269-75
references.pmid: 20514206
references.citation: Stroke. 1990 Jan;21(1):1-3
references.pmid: 2405545
references.citation: Clin Chem. 2003 Oct;49(10):1733-9
references.pmid: 14500614
references.citation: Neurol Res. 2011 May;33(4):433-8
references.pmid: 21535944
references.citation: Gene Ther. 2007 Apr;14(7):621-5
references.pmid: 17235293
references.citation: Brain Res. 2009 Jul 28;1282:142-55
references.pmid: 19477169
references.citation: J Cereb Blood Flow Metab. 2010 Jun;30(6):1079-93
references.pmid: 20354545
references.citation: J Neurosci. 2000 Sep 15;20(18):7037-42
references.pmid: 10995849
references.citation: NeuroRx. 2004 Jan;1(1):36-45
references.pmid: 15717006
references.citation: BMC Neurosci. 2006 Jul 17;7:56
references.pmid: 16846501
references.citation: Stroke. 2009 Sep;40(9):3028-33
references.pmid: 19628804
references.citation: Neuroscience. 2008 Mar 3;152(1):8-17
references.pmid: 18255236
references.citation: FEBS Lett. 2004 Jun 1;567(1):129-35
references.pmid: 15165905
references.citation: J Cereb Blood Flow Metab. 2010 Aug;30(8):1412-31
references.pmid: 20485296
references.citation: J Mol Neurosci. 2012 Mar;46(3):483-91
references.pmid: 21845429
references.citation: Nat Med. 2006 Apr;12(4):441-5
references.pmid: 16565723
references.citation: Circ Res. 2013 Sep 27;113(8):1013-22
references.pmid: 23780386
references.citation: Neurol Sci. 2013 Aug;34(8):1391-6
references.pmid: 23224583
references.citation: Acta Med Okayama. 2011 Aug;65(4):219-23
references.pmid: 21860527
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):488-98
references.pmid: 17704356
references.citation: Brain Res. 2011 Jan 7;1367:347-59
references.pmid: 20950592
references.citation: Neuroscientist. 2008 Dec;14(6):626-36
references.pmid: 19029060
references.citation: Curr Pharm Des. 2013;19(6):1085-9
references.pmid: 23016686
references.citation: Neurosci Lett. 2001 Jun 1;305(1):41-4
references.pmid: 11356303
references.citation: Pharmacotherapy. 2010 Jul;30(7 Pt 2):55S-61S
references.pmid: 20575623
references.citation: J Cereb Blood Flow Metab. 2008 Oct;28(10):1674-85
references.pmid: 18560439
references.citation: Front Neurol. 2013 Apr 03;4:32
references.pmid: 23565108
references.citation: Exp Neurol. 2006 Jul;200(1):38-49
references.pmid: 16624294
references.citation: PLoS One. 2012;7(11):e50028
references.pmid: 23185522
references.citation: Arch Neurol. 1997 Dec;54(12):1466-74
references.pmid: 9400355
references.citation: J Cereb Blood Flow Metab. 2009 Nov;29(11):1816-24
references.pmid: 19638998
references.citation: Stroke. 2013 Mar;44(3):745-52
references.pmid: 23422086
references.citation: N Engl J Med. 1995 Dec 14;333(24):1581-7
references.pmid: 7477192
references.citation: J Neurosurg. 2005 Aug;103(2):289-97
references.pmid: 16175859
references.citation: Stroke. 2002 Mar;33(3):831-6
references.pmid: 11872911
references.citation: Curr Opin Pharmacol. 2008 Feb;8(1):82-9
references.pmid: 18226583
references.citation: Ann Neurol. 1981 Feb;9(2):131-41
references.pmid: 7235629
references.citation: Handb Clin Neurol. 2009;92:43-66
references.pmid: 18790269
references.citation: Neuroscience. 2005;134(1):225-31
references.pmid: 15963646
references.citation: Blood. 2004 Apr 1;103(7):2610-6
references.pmid: 14630814
references.citation: Nat Rev Drug Discov. 2018 Jul;17(7):467
references.pmid: 29904192
references.citation: Stroke. 2006 Jun;37(6):1399-406
references.pmid: 16690896
references.citation: J Neurol Sci. 2012 Dec 15;323(1-2):221-7
references.pmid: 23046750
references.citation: Neurology. 2006 May 23;66(10):1550-5
references.pmid: 16717217
references.citation: Stroke. 2003 Sep;34(9):2165-70
references.pmid: 12907822
references.citation: Comp Med. 2004 Oct;54(5):486-96
references.pmid: 15575362
references.citation: J Neurosci. 2004 Jan 21;24(3):671-8
references.pmid: 14736853
references.citation: Stroke. 2008 Jan;39(1):100-4
references.pmid: 18063832
references.citation: Eur J Pharmacol. 2002 Nov 29;455(2-3):91-100
references.pmid: 12445574
references.citation: Brain Res. 1999 Sep 18;842(1):92-100
references.pmid: 10526099
references.citation: Brain Res. 2003 Sep 12;984(1-2):63-75
references.pmid: 12932840
references.citation: Eur J Neurosci. 2005 Oct;22(7):1597-608
references.pmid: 16197500
references.citation: Stroke. 2013 Oct;44(10):2901-3
references.pmid: 23908067
references.citation: J Cereb Blood Flow Metab. 2005 Nov;25(11):1505-16
references.pmid: 15959464
references.citation: J Cereb Blood Flow Metab. 2011 Mar;31(3):924-33
references.pmid: 20877384
references.citation: Neurol Res. 2007 Apr;29(3):274-82
references.pmid: 17509227
references.citation: Stroke. 2008 Dec;39(12):3372-7
references.pmid: 18927459
references.citation: Neurobiol Dis. 2001 Oct;8(5):834-46
references.pmid: 11592852
references.citation: Brain Res. 2001 Mar 2;893(1-2):104-12
references.pmid: 11222998
references.citation: J Neurosci. 2001 Oct 1;21(19):7724-32
references.pmid: 11567062
references.citation: Neuroscience. 2009 Jan 12;158(1):167-76
references.pmid: 18588950
references.citation: Stroke. 2003 Jan;34(1):40-6
references.pmid: 12511748
references.citation: J Cereb Blood Flow Metab. 1999 Jun;19(6):624-33
references.pmid: 10366192
references.citation: Stroke. 2011 Aug;42(8):2351-5
references.pmid: 21778445
references.citation: J Neurosci. 1997 Jun 1;17(11):4223-35
references.pmid: 9151739
references.citation: J Cereb Blood Flow Metab. 1999 Sep;19(9):1020-8
references.pmid: 10478654
references.citation: J Cereb Blood Flow Metab. 2004 Jul;24(7):720-7
references.pmid: 15241180
references.citation: Neurochem Int. 2012 Dec;61(7):1065-71
references.pmid: 22892277
references.citation: Ann N Y Acad Sci. 2010 Oct;1207:123-33
references.pmid: 20955435